超越新陈代谢:性功能障碍和减肥药物
Jenyfer M Fuentes-Mendoza1, Marcio J Concepción-Zavaleta1, Jeny J Mendoza-Godoy2
1Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima 15067, Peru.
Sexual medicine reviews
|December 22, 2025
概括
新的减肥药物对性功能有多种影响,对男性有一些好处,但对女性的数据有限. 需要更多的研究来了解这些对性健康的影响.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 性医学性医学性医学性医学
背景情况:
- 肥胖与性功能障碍 (SD) 通过荷尔蒙,血管,代谢和心理社会因素有关.
- 减肥通常会改善性健康,但新的减肥药物的影响尚不清楚.
研究的目的:
- 审查目前关于减肥药物如何影响性功能的证据.
- 综合临床结果,探索机制,并确定研究差距.
主要方法:
- 一个全面的叙事审查研究从PubMed,Scopus和Embase.
- 搜索了与肥胖,SD和药物治疗有关的术语.
- 包括使用验证仪器 (FSFI,IIEF) 或临床报告报告报告性结果的研究.
主要成果:
- GLP-1受体激动剂对男性性功能和丸激素有很大的前景.
- 关于女性性功能的数据有限;一些药物可能有副作用.
- 其他药物影响性欲和心理健康;性终点通常是次要的.
结论:
- 减肥药物通过各种途径影响性健康,但证据不一致.
- 性别特定的数据和对伴随性疾病的研究很少.
- 未来的试验需要验证性功能测量作为主要终点,按性别分层.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
218
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
218
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
153
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153
Drug Dosing: Obese Patients
195
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
195
Disorders of the Male Reproductive System
3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Antidepressant Drugs: MAOIs and Other Agents
765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234


